Do Not Sell My Personal Information (CA Residents Only). In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. But realizing value in practice usually is a difficult endeavor. Ill be sticking to the stocks that are actually working. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. Our 3 Top Picks. Nasdaq If you missed that action, you missed all the gains. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. In this case, shares rallied about four-fold in just a few days. So, what goes wrong? In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. The biotech stock promptly crashed by more than 30%. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. The short answer is: everything. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. The Motley Fool->. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Theres even room for more lines. Pricing likely would be favorable, given the lack of alternative treatments. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Written by Investors need to understand the risk profile here. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. You canfollow Will on Twitterat @HealyWriting. The Ocugen deal is a way to salvage some limited value. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Hold) without suggesting a price target. OCGN does not even appear to have an apparent reason to exist. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. But just because a company does not have crippling debt doesnt mean its a buy. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Not an offer or recommendation by Stocktwits. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Create your Watchlist to save your favorite quotes on Nasdaq.com. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. To make the world smarter, happier, and richer. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. The Motley Fool has a disclosure policy. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Type a symbol or company name. The second is that the balance sheet still needs some help. The stock had gained some traction after they announced the Ocugen merger in April. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. So far, that merger hasnt worked out for Histogenics former shareholders. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. The average Ocugen stock price for the last 52 weeks is 2.10. These options will be cheaper than owning the stock itself. Ocugen had to go an unusual route to go public. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. However, sometimes the optimism isn't justified. Companies will inevitably be optimistic about their prospects for success (at least publicly). Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Investing is always a game of balancing risk and reward. Making the world smarter, happier, and richer. Sign up below to get this incredible offer! Invest better with The Motley Fool. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. These symbols will be available throughout the site during your session. (See OCGN stock analysis on TipRanks). After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. To be sure, current cash isnt enough. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Sign up below to get this incredible offer! CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Click here to see what Matt has up his sleeve now. Accordingly, the analyst rates OCGN a Neutral (i.e. *Average returns of all recommendations since inception. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Theres an opportunity here. But there is no question some big-name stocks performed better than others along the way. It has no treatments to offer the market. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Keith Speights has no position in any of the stocks mentioned. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Type a symbol or company name. The FDA's decision not to issue EUA really wasn't all that surprising, though. The statistics support having long-term exposure to this asset class. Ocugen. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. That's right -- they think these 10 stocks are even better buys. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Emergency Use . 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. The latest closing stock price for Ocugen as of March 03, 2023 is. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Conditions have only become worse since that time. Maybe OCGN stock will be one of them again. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Guys, theres no revenue here! The median estimate. 1125 N. Charles St, Baltimore, MD 21201. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. Investors were hopeful that the small drugmaker would be able to win U.S. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Ocugen isnt a promotional, fly-by-night penny stock. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. As of this writing, Vince Martin has no positions in any securities mentioned. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18.